Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Hutson on Tivozanib for Renal Cell Carcinoma

June 13th 2013

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).

Dr. Figlin on Sequencing mTOR Inhibitors and TKIs in RCC

June 12th 2013

Robert Figlin, MD, FACP, discusses the sequencing of mTOR inhibitors and tyrosine kinase inhibitors in renal cell carcinoma.

The Urology Center of Colorado: Raising the Bar for Collaborative Urologic Care

June 11th 2013

"If you build it, they will come," became a catchphrase thanks to the 1989 movie "Field of Dreams." For the founders of The Urology Center of Colorado (TUCC), it was more than just a saying.

FDA Rejects Tivozanib for Kidney Cancer, Recommends Additional Clinical Study

June 10th 2013

The FDA has rejected a new drug application for tivozanib for the treatment of advanced renal cell carcinoma, recommending an additional clinical trial to address concerns over existing clinical data.

Screening Remains Critical to Optimal Management of Prostate Cancer

May 28th 2013

The mortality rate from prostate cancer has declined significantly in the past few decades; however, there is much debate over how much PSA screening contributed to that decline.

Dr. Concepcion on Robotic Surgery Adverse Event Spikes

May 24th 2013

Raoul S. Concepcion, MD, from the Urology Associates, PC, Nashville, TN, discusses a recent FDA investigation into spikes in reported adverse events associated with the use of robotic-assisted surgery.

Dr. Deepak Kapoor Discusses PSA Screening Guidelines

May 22nd 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, provides his opinion on current prostate cancer screening recommendations.

Ablative Therapies for Small Renal Masses

May 22nd 2013

A peer-reviewed summary of the ablative techniques currently available for the treatment of small renal masses.

Early Results Robust for New PD-L1 Immunotherapy Agent

May 15th 2013

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

"Brothers in Arms"

May 7th 2013

We need to begin to migrate toward a system that embraces evidence-based medicine, and begin the development of protocols and the measurement of quality metrics.

Dramatic Shortage of Urologists on Horizon

May 6th 2013

An estimated 16,000 urologists will be needed to provide specialty care by 2025, but estimates of the number of urologists likely to be in practice at that time range between 6800 and 7400.

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

May 6th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

AUA Abstract Roundup

May 6th 2013

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

The Value of Office-Based Prescription Dispensing

May 3rd 2013

Steve Dobbs, the CEO of Urologic Specialists of Oklahoma, Inc, discusses the viability, legality, and successful implementation of an office-based medication-dispensing solution.

ODAC Votes Against Tivozanib in Renal Cell Carcinoma

May 2nd 2013

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

Dr. Dreicer on an Alternate Sunitinib Schedule in mRCC

April 1st 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses a 2-weeks-on and 1-week-off (2/1) schedule of sunitinib for patients with metastatic renal cell carcinoma.

AGS-003 Vaccine Achieves Survival Benefits in mRCC

March 26th 2013

AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.

Studies Determine Smokers' Risks of Recurrence, Progression, and Survival in Bladder Cancer

March 20th 2013

An international group of investigators provided first-time evidence of the impact of smoking on outcomes in bladder cancer in results from two studies.

Blazing the Oregon Trail: Oregon Urology Institute Nurtures Its Position as a Urology Care Leader

March 19th 2013

An interview with Bryan Mehlhaff, MD, and retired physician Robert Litin, MD, about how Oregon Urology Institute is adapting its well-established practice to an ever-shifting healthcare landscape.

Dr. Hoffman on the Urologist's Influence on Treatment Choice

March 11th 2013

Karen E. Hoffman, MD, MHSc, MPH, from the MD Anderson Cancer Center, describes the diagnosing urologist's influence on the initial treatment selected for elderly men with favorable prostate cancer.